Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

A new UCLA investigator-initiated study has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer, a disease that has historically been difficult to treat.